AnaptysBio Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AnaptysBio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View analyst ratings for AnaptysBio or view top-rated stocks.

3 brokerages have issued 12-month price objectives for AnaptysBio's shares. Their ANAB stock forecasts range from $33.00 to $46.00. On average, they predict AnaptysBio's share price to reach $39.50 in the next twelve months. This suggests a possible upside of 79.8% from the stock's current price.
View analysts' price targets for AnaptysBio or view top-rated stocks among Wall Street analysts.

AnaptysBio's stock was trading at $34.75 at the beginning of 2022. Since then, ANAB stock has decreased by 36.8% and is now trading at $21.97.
View the best growth stocks for 2022 here.

AnaptysBio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for AnaptysBio.

AnaptysBio, Inc. (NASDAQ:ANAB) posted its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by $0.44. The biotechnology company had revenue of $0.97 million for the quarter, compared to analyst estimates of $8.08 million. AnaptysBio had a negative net margin of 143.46% and a negative trailing twelve-month return on equity of 20.44%.
View AnaptysBio's earnings history.

Some companies that are related to AnaptysBio include EQRx (EQRX), Arvinas (ARVN), ACADIA Pharmaceuticals (ACAD), HUTCHMED (HCM), Schrödinger (SDGR), Sage Therapeutics (SAGE), Global Blood Therapeutics (GBT), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), OPKO Health (OPK), Arcus Biosciences (RCUS), Xenon Pharmaceuticals (XENE), Amphastar Pharmaceuticals (AMPH), Xencor (XNCR) and Lyell Immunopharma (LYEL).
View all of ANAB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.48%), BlackRock Inc. (6.47%), Federated Hermes Inc. (5.69%), State Street Corp (3.40%), Frazier Life Sciences Management L.P. (3.19%) and Dimensional Fund Advisors LP (3.16%). Company insiders that own AnaptysBio stock include Ecor1 Capital, Llc, Eric J Loumeau and Hamza Suria.
View institutional ownership trends for AnaptysBio.

ANAB stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Eversept Partners LP, Arrowstreet Capital Limited Partnership, BlackRock Inc., Acadian Asset Management LLC, Citigroup Inc., Los Angeles Capital Management LLC, and Vanguard Group Inc.. Company insiders that have sold AnaptysBio company stock in the last two years include Eric J Loumeau, and Hamza Suria.
View insider buying and selling activity for AnaptysBio or view top insider-selling stocks.

ANAB stock was acquired by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Deep Track Capital LP, Woodline Partners LP, Great Point Partners LLC, Dimensional Fund Advisors LP, State Street Corp, Rock Springs Capital Management LP, and Bank of America Corp DE.
View insider buying and selling activity for AnaptysBio or or view top insider-buying stocks.

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANAB stock can currently be purchased for approximately $21.97.

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $619.33 million and generates $63.17 million in revenue each year. The biotechnology company earns $-57.80 million in net income (profit) each year or ($2.75) on an earnings per share basis.

AnaptysBio employs 102 workers across the globe.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for AnaptysBio is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at [email protected].